Osteosarcoma treatment - where do we stand? A state of the art review.
作者： Anja Luetke , Paul A. Meyers , Ian Lewis , Heribert Juergens
DOI: 10.1016/J.CTRV.2013.11.006
关键词: Oncology 、 Systemic chemotherapy 、 Alpha interferon 、 Mifamurtide 、 Osteosarcoma 、 Medicine 、 Chemotherapy 、 State of the art review 、 Internal medicine 、 Poor prognosis 、 Disease 、 Surgery
摘要: Long-term outcome for patients with high-grade osteosarcoma has improved with the addition of systemic chemotherapy, but subsequent progress has been less marked. Modern, multiagent, dose-intensive chemotherapy in conjunction with surgery achieves a 5-year event-free survival of 60–70% in extremity localized, non-metastatic disease. A major, as yet unsolved, problem is the poor prognosis for metastatic relapse or recurrence, and for patients with axial disease. This article reviews the current state of the art of systemic …
elsevier.com
sci-hub.se 参考文章(99)
Brigitte C. Widemann, Frank M. Balis, Beate Kempf-Bielack, Stefan Bielack, Charles B. Pratt, Stefano Ferrari, Gaetano Bacci, Alan W. Craft, Peter C. Adamson, High-Dose Methotrexate-Induced Nephrotoxicity in Patients with Osteosarcoma: Incidence, Treatment, and Outcome Cancer. ,vol. 100, pp. 2222- 2232 ,(2004) , 10.1002/CNCR.20255
Alexander J Chou, David S Geller, Richard Gorlick, Therapy for osteosarcoma: where do we go from here? Pediatric Drugs. ,vol. 10, pp. 315- 327 ,(2008) , 10.2165/00148581-200810050-00005
N. Marina, S. Bielack, J. Whelan, S. Smeland, M. Krailo, M. R. Sydes, T. Butterfass-Bahloul, G. Calaminus, M. Bernstein, International collaboration is feasible in trials for rare conditions: The EURAMOS experience Cancer treatment and research. ,vol. 152, pp. 339- 353 ,(2007) , 10.1007/978-1-4419-0284-9_18
G. Bacci, A. Longhi, C. Forni, E. Setola, E.S. Ferrari, Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders European Journal of Cancer. ,vol. 39, pp. 488- 494 ,(2003) , 10.1016/S0959-8049(03)00546-X
P.M. Anderson, P. Meyers, E. Kleinerman, K. Venkatakrishnan, D.P. Hughes, C. Herzog, W. Huh, R. Sutphin, Y.M. Vyas, V. Shen, A. Warwick, N. Yeager, C. Oliva, B. Wang, Y. Liu, A. Chou, Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments Pediatric Blood & Cancer. ,vol. 61, pp. 238- 244 ,(2014) , 10.1002/PBC.24686
Gaetano Bacci, Stefano Ferrari, Franco Bertoni, Pietro Ruggieri, Piero Picci, Alessandra Longhi, Roberto Casadei, Nicola Fabbri, Cristiana Forni, Michela Versari, Mario Campanacci, Long-Term Outcome for Patients With Nonmetastatic Osteosarcoma of the Extremity Treated at the Istituto Ortopedico Rizzoli According to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: An Updated Report Journal of Clinical Oncology. ,vol. 18, pp. 4016- 4027 ,(2000) , 10.1200/JCO.2000.18.24.4016
V H Bramwell, M Burgers, R Sneath, R Souhami, A T van Oosterom, P A Voûte, J Rouesse, D Spooner, A W Craft, R Somers, A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. Journal of Clinical Oncology. ,vol. 10, pp. 1579- 1591 ,(1992) , 10.1200/JCO.1992.10.10.1579
P A Meyers, R Gorlick, G Heller, E Casper, J Lane, A G Huvos, J H Healey, Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. Journal of Clinical Oncology. ,vol. 16, pp. 2452- 2458 ,(1998) , 10.1200/JCO.1998.16.7.2452
Edwin Choy, Francis Hornicek, Laura MacConaill, David Harmon, Zeeshan Tariq, Levi Garraway, Zhenfeng Duan, High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer. ,vol. 118, pp. 2905- 2914 ,(2012) , 10.1002/CNCR.26617
Jolieke G. van Oosterwijk, Jakob K. Anninga, Hans Gelderblom, Anne-Marie Cleton-Jansen, Judith V.M.G. Bovée, Update on targets and novel treatment options for high-grade osteosarcoma and chondrosarcoma. Hematology-oncology Clinics of North America. ,vol. 27, pp. 1021- 1048 ,(2013) , 10.1016/J.HOC.2013.07.012